Mitochondrial Complex I Deficiency in Parkinson's Disease

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Journal of Neurochemistry

• Publication date

  1989-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1471-4159.1990.tb02325.xPMID 2154550
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lounging in a lysosome: the intracellular lifestyle of Coxiella burnetii

  2007cited by this paper
• Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease

  1989cited by this paper
• Mitochondrial complex I deficiency in Parkinson's disease.

  1989cited by this paper
• Molecular defects of NADH-ubiquinone oxidoreductase (Complex I) in mitochondrial diseases

  1988cited by this paper
• Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies

  1988cited by this paper
• MOLECULAR BASIS OF MITOCHONDRIAL MYOPATHIES: POLYPEPTIDE ANALYSIS IN COMPLEX-1 DEFICIENCY

  1988cited by this paper
• 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro.

  1988cited by this paper
• Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens.

  1988cited by this paper
• Molecular basis of mitochondrial myopathies: polypeptide analysis in complex-I deficiency.

  1988cited by this paper
• Normal oxidative damage to mitochondrial and nuclear DNA is extensive.

  1988cited by this paper
• Reoxygenation in perfused, hypoxic heart causes a mitochondrial complex I defect

  1988cited by this paper
• A Dopaminergic Cell Line Variant Resistant to the Neurotoxin 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine

  1987cited by this paper
• Biochemical Events in the Development of Parkinsonism Induced by 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine

  1987cited by this paper
• Increased nigral iron content in postmortem parkinsonian brain.

  1987cited by this paper
• Photolabelling of a mitochondrially encoded subunit of NADH dehydrogenase with [3H]dihydrorotenone

  1987cited by this paper
• Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP.

  1986cited by this paper
• Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria.

  1986cited by this paper
• Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity.

  1985cited by this paper
• Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.

  1985cited by this paper
• Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.

  1985cited by this paper
• The specific vulnerability of the substantia nigra to MPTP is related to the presence of transition metals.

  1985cited by this paper
• Animal mitochondrial DNA: an extreme example of genetic economy.

  1985cited by this paper
• Role of metals in oxygen radical reactions.

  1985cited by this paper
• Paraquat: model for oxidant-initiated toxicity.

  1984cited by this paper
• Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP.

  1984cited by this paper
• Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey.

  1984cited by this paper
• A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1983cited by this paper
• Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.

  1983cited by this paper
• Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

  1979cited by this paper
• Chronic Parkinsonism secondary to intravenous injection of meperidine analogues.

  1979cited by this paper
• Repair of pyrimidine dimers in nuclear and mitochondrial DNA of yeast irradiated with low doses of ultraviolet light.

  1975cited by this paper
• Regulation of adipose tissue pyruvate dehydrogenase by insulin and other hormones.

  1971cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper
• [43] Preparation and properties of DPNH-coenzyme Q reductase (complex I of the respiratory chain)

  1967cited by this paper
• [40] Preparations of succinate—cytochrome c reductase and the cytochrome b-c1 particle, and reconstitution of succinate-cytochrome c reductase

  1967cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Breaking the Bonds of Aging: The Underappreciated Roles of Aberrant Cysteine Crosslinks and Protective Thiol Interventions.

  2026cites this paper
• Heat shock protein 10 as a chaperone modulating α‐synuclein amyloid fibril formation

  2026cites this paper
• Bridging pathway dysfunction and therapy: novel compounds for neuroprotection

  2026cites this paper
• The interplay of homeostasis, inflammation, and oxidative stress in neurodegenerative disorders: the role of biological markers, antioxidants, lithium, and TMS — a proposed framework for preventing neurodegenerative disorders through biomarkers and multimodal therapies

  2026cites this paper
• New Insights on Mitochondria-Targeted Neurological Drugs

  2026cites this paper
• The lifespan continuum of brain disorders: investigating links between neurodevelopmental and neurodegenerative disease-chicken or egg?

  2026cites this paper
• Unravelling the novel insights between miR-7 and Parkinson’s disease (PD)

  2026cites this paper
• A paradigm shift: from precision medicine to precision health in neurodegenerative conditions and aging

  2026cites this paper
• The Nodding syndrome cerebrospinal fluid proteome: a lens into neurodevelopmental failure consistent with environmentally triggered MECP2 dysregulation?

  2026cites this paper
• Consensus Molecules Associated with Parkinson's Disease.

  2026cites this paper
• MPTP and rotenone cause dopaminergic neuronal death by increasing DDIT4 promoter lactylation.

  2026cites this paper
• An update on the monogenic causes of Parkinson's disease: Impact on patient stratification and personalised medicine.

  2026cites this paper
• Targeting PI3K/Akt/mTOR with fisetin mechanistic and therapeutics insights for Parkinson’s disease

  2026cites this paper
• The effects of ursodeoxycholic acid on Parkinson’s disease, a mechanistic review of the recent evidence

  2025cites this paper
• Glucocorticoids and Mitochondrial Dysfunction in Parkinson’s Disease

  2025cites this paper
• Study insights in the role of PGC-1α in neurological diseases: mechanisms and therapeutic potential

  2025cites this paper
• Deficient AMPK-SENP1-Sirt3 signaling impairs mitochondrial complex I function in Parkinson’s disease model

  2025cites this paper
• Caloric Restriction Mimetics as Priming Agents of Mesenchymal Stem Cells Secretome to Enhance Regenerative Responses to Parkinson’s Disease

  2025cites this paper
• Organic cation transporter 3 on neuronal mitochondria mediates MPP+-induced mitochondrial dysfunction and neurotoxicity in a TIMM22-dependent manner

  2025cites this paper
• Understanding the Pre-Clinical Stages of Parkinson’s Disease: Where Are We in Clinical and Research Settings?

  2025cites this paper
• Flavonoids and their role in oxidative stress, inflammation, and human diseases.

  2025cites this paper
• Mitophagy in Neurons: Mechanisms Regulating Mitochondrial Turnover and Neuronal Homeostasis.

  2025cites this paper
• Development of In Vitro Parkinson's Disease Model Mediated by MPP+ and α‐Synuclein Using Wharton's Jelly Mesenchymal Stem Cells

  2025cites this paper
• The neuroprotective role of CncC in a Drosophila model of Parkinson’s disease

  2025cites this paper
• Role of Cellular Senescence in Parkinson’s Disease: Potential for Disease-Modification Through Senotherapy

  2025cites this paper
• MOLECULARss HYDROGEN THERAPY: A "DEMOCRATIC" EMERGING STRATEGY AGAINST AGING AND AGE-RELATED DISEASES.

  2025cites this paper
• Integrated Behavioral and Proteomic Characterization of MPP+-Induced Early Neurodegeneration and Parkinsonism in Zebrafish Larvae

  2025cites this paper
• Mitochondrial Dysfunction in Neurodegenerative Diseases

  2025cites this paper
• Oxidative Stress and Mitochondrial Impairment: Key Drivers in Neurodegenerative Disorders.

  2025cites this paper
• Exosome-Mediated Mitochondrial Regulation: A Promising Therapeutic Tool for Alzheimer’s Disease and Parkinson’s Disease

  2025cites this paper
• Identifying blood mitochondrial DNA copy number as a biomarker for development of neurodegenerative diseases: Evidence from Mendelian randomization analysis.

  2025cites this paper
• Linking Cell Architecture to Mitochondrial Signaling in Neurodegeneration: The Role of Intermediate Filaments

  2025cites this paper
• The many roads to dementia: a systems view of Alzheimer's disease

  2025cites this paper
• Mitochondria-Mediated Mechanisms of Ferroptosis in Neurological Diseases

  2025cites this paper
• Cell-Free DNA and Mitochondria in Parkinson’s Disease

  2025cites this paper
• Genetic convergence in brain aging and neurodegeneration: from cellular mechanisms to therapeutic targets

  2025cites this paper
• Investigating the ageing-Parkinson’s disease nexus: standardisation of in vitro models and techniques by the PD-AGE network

  2025cites this paper
• Long non-coding RNA Cerox1 targets components of the mitochondrial electron transport chain to regulate the memory impairment caused by sleep deprivation

  2025cites this paper
• Mitochondria-Targeted Nanosystems in the Treatment of Central Nervous System Diseases

  2025cites this paper
• Mitochondrial dysfunction in cellular senescence: a bridge to neurodegenerative disease

  2025cites this paper
• Synapse-related protein alterations and estradiol deficiency associate with early Parkinsonism in female A53T-α-synuclein transgenic mice fed on a high-fat diet

  2025cites this paper
• Ubiquitin signaling in PINK1/Parkin-dependent mitophagy.

  2025cites this paper
• Complex I superoxide anion production is necessary and sufficient for complex I inhibitor-induced dopaminergic neurodegeneration in Caenorhabditis elegans

  2025cites this paper
• Lasting Impact: Exploring the Brain Mechanisms that Link Traumatic Brain Injury to Parkinson’s Disease

  2025cites this paper
• Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances

  2025cites this paper
• α-Synuclein pathology and mitochondrial dysfunction: Toxic partners in Parkinson's disease.

  2025cites this paper
• Mitochondrial Dysfunction in Neurodegenerative Diseases

  2025cites this paper
• Mitochondrial stress disassembles nuclear architecture through proteolytic activation of PKCδ and Lamin B1 phosphorylation in neuronal cells: implications for pathogenesis of age-related neurodegenerative diseases

  2025cites this paper
• Effects of herbaceous bioflavonoid herbacetin on oxidative stress, and alpha-synuclein regulation, programmed cell death in a Parkinson illness

  2025cites this paper
• Sex-dimorphic effects of neuromelanin buildup in rodent nigral dopamine neurons: implications for sex-biased vulnerability in Parkinson’s disease

  2025cites this paper
• Current trends and future prospects of N-acetylcysteine utilizations in Parkinson's disease: A literature network analysis

  2025cites this paper
• Constraint-based modeling of bioenergetic differences between synaptic and non-synaptic components of dopaminergic neurons in Parkinson’s disease

  2025cites this paper
• Unraveling Parkinson's disease: The mystery of mitochondria and the role of aging

  2025cites this paper
• Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances

  2025cites this paper
• Interaction Between α-Synuclein and DJ-1 in Parkinson’s Disease

  2025cites this paper
• STING Signaling Pathway as a Target for Neuroprotective Therapy in Parkinson’s Disease

  2025cites this paper
• Immune cell metabolic dysfunction in Parkinson’s disease

  2025cites this paper
• Chromogen-based double immunohistochemical detection of mitochondrial respiratory chain deficiencies in human brain tissue

  2025cites this paper
• The Ketogenic Diet Through a Metabolomic Lens: Biochemical Pathways, Therapeutic Applications, and Analytical Challenges

  2025cites this paper
• Immunity in Parkinson's disease - The role of innate responses.

  2025cites this paper
• The role of gasotransmitters in Parkinson's disease: Interplay of nitric oxide, carbon monoxide, and hydrogen sulfide

  2025cites this paper
• Bioinformatics Identification of Shared Signaling Pathways and Core Targets Linking Benzo[a]pyrene Exposure to HCC Progression.

  2025cites this paper
• The Mitochondrial Connection in Parkinson's Disease.

  2025cites this paper
• Epigenetic regulation of the respiratory chain by a mitochondrial distress-related redox signal

  2025cites this paper
• Strategies to rescue mitochondria in Parkinson's disease: The significance of mitochondrial transfer.

  2025cites this paper
• Hypoxia ameliorates neurodegeneration and movement disorder in a mouse model of Parkinson’s disease

  2025cites this paper
• Potentiation of mitochondrial function by mitoDREADD-Gs reverses pharmacological and neurodegenerative cognitive impairment in mice

  2025cites this paper
• Iron mishandling in the brain and periphery in Parkinson’s disease

  2025cites this paper
• Animal Models for the Study of Neurological Diseases and Their Link to Sleep

  2025cites this paper
• A Perspective on the Role of Mitochondrial Biomolecular Condensates (mtBCs) in Neurodegenerative Diseases and Evolutionary Links to Bacterial BCs

  2025cites this paper
• Long non-coding RNA Cerox1 targets components of the mitochondrial electron transport chain to regulate the memory impairment caused by sleep deprivation

  2025cites this paper
• The interplay between obesity and triglyceride-glucose index in modulating Parkinson's disease risk: A cross-sectional NHANES study of middle-aged and young adults.

  2025cites this paper
• Ferroptosis-related stress during aging and its relevance to disease.

  2025cites this paper
• The role of mitochondrial genetics in Parkinson's disease: Long-read sequencing as an emerging method.

  2025cites this paper
• Etiopathogenesis, Clinical Manifestations, and Management of Parkinson's Disease

  2025cites this paper
• Cannabidiol and Parkinson's disease: Investigating receptor interactions and their therapeutic implications.

  2025cites this paper
• Neuroprotective Agents: Implications for Parkinson's Disease Treatment.

  2025cites this paper
• Mapping the global research landscape of mitophagy in Parkinson's disease: a bibliometric and visualization analysis

  2025cites this paper
• Spatiotemporal crosstalk among mitochondrial dynamics, NLRP3 inflammasome activation, and histone lactylation drives α-synuclein pathology in prodromal Parkinson’s disease

  2025cites this paper
• Genetic predispositions and nutritional strategies: a review of nutrigenomics in Parkinson's disease.

  2025cites this paper
• Proteomic Analysis of Substantia Nigra Reveals Molecular Insights Into the Neuroprotection Effect of Rosmarinic Acid Treatment in MPTP‐Induced Mouse Model of Parkinson's Disease

  2025cites this paper
• Chemical Hypoxia Induces Pyroptosis in Neuronal Cells by Caspase-Dependent Gasdermin Activation

  2024cites this paper
• Changes in Bacterial Gut Composition in Parkinson’s Disease and Their Metabolic Contribution to Disease Development: A Gut Community Reconstruction Approach

  2024cites this paper
• Mitochondria Dysfunction and Neuroinflammation in Neurodegeneration: Who Comes First?

  2024cites this paper
• Inflachromene ameliorates Parkinson's disease by targeting Nrf2-binding Keap1

  2024cites this paper
• Distinct mechanisms underlying the therapeutic effects of low-molecular-weight heparin and chondroitin sulfate on Parkinson's disease.

  2024cites this paper
• Effects and mechanisms of bisphenols exposure on neurodegenerative diseases risk: A systemic review.

  2024cites this paper
• Ameliorating Mitochondrial Dysfunction for the Therapy of Parkinson's Disease.

  2024cites this paper
• Hypoxia and intra-complex genetic suppressors rescue complex I mutants by a shared mechanism.

  2024cites this paper
• Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson’s disease

  2024cites this paper
• Significance of Mitochondrial Dysfunction in the Pathogenesis of Parkinson's Disease.

  2024cites this paper
• Ferroptosis regulation through Nrf2 and implications for neurodegenerative diseases

  2024cites this paper
• A naturally occurring variant of SHLP2 is a protective factor in Parkinson’s disease

  2024cites this paper
• The PINK1/Parkin pathway of mitophagy exerts a protective effect during prion disease

  2024cites this paper
• Effect of Diacetylcurcumin Manganese Complex on Rotenone-Induced Oxidative Stress, Mitochondria Dysfunction, and Inflammation in the SH-SY5Y Parkinson’s Disease Cell Model

  2024cites this paper
• Outcomes of dietary interventions in the prevention and progression of Parkinson's disease: A literature review

  2024cites this paper
• Metabolic Dysfunction in Parkinson’s Disease: Unraveling the Glucose–Lipid Connection

  2024cites this paper
• A Vulnerable Subtype of Dopaminergic Neurons Drives Early Motor Deficits in Parkinson’s Disease

  2024cites this paper
• Cerebellar microglia: On the edge between neuroinflammation and neuroregulation

  2024cites this paper
• Phytochemicals in Parkinson’s Disease: a Pathway to Neuroprotection and Personalized Medicine

  2024cites this paper